TPO and diabetes mellitus: Gliclazide therapy has also been shown to reduce IL-6 levels in diabetics presenting with poor glucose control (60), and similar to metformin we speculate that changes in the IL-6/TPO axis could mediate feedback effects on platelet generation, turnover and the average size of platelets.